AI assistant
BridgeBio Pharma, Inc. — Director's Dealing 2020
Jun 3, 2020
30604_dirs_2020-06-03_c04d025a-d63e-48d6-acf4-e0b25c92349f.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: BridgeBio Pharma, Inc. (BBIO)
CIK: 0001743881
Period of Report: 2020-06-01
Reporting Person: STEPHENSON BRIAN C (See Remarks)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2020-06-01 | Common Stock | S | 6300 | $29.3068 | Disposed | 309616 | Direct |
| 2020-06-01 | Common Stock | S | 900 | $29.7423 | Disposed | 308716 | Direct |
Footnotes
F1: This transaction was effected pursuant to a Rule 10b5-1 sales plan adopted by the Reporting Person on December 3, 2019.
F2: Represents the weighted average sale price of the shares sold from $28.66 to $29.64 per share. The Reporting Person will provide, upon request by the Commission staff, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 and 3.
F3: Represents the weighted average sale price of the shares sold from $29.66 to $29.875 per share.